Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01871441 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · PHASE2 · terminated · last registry update 2025-05-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial was closed due to poor accrual.” | – | Registry record, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FKBP1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-29Results posted on the registry: Medical College of Wisconsin, Hydroxyurea + Rabbit-ATG (NCT03263559)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-04-06Results posted on the registry: ITM Solucin GmbH, 177Lu-edotreotide PRRT + Everolimus (NCT03049189)
- 2026-03-16Phase 3 first posted: AgelessRx, Rapamycin + Naltrexone (NCT07475546)
- 2026-02-27Results posted on the registry: Columbia University, Siplizumab + Cyclophosphamide 50mg (NCT06078696)
- 2026-02-17Phase 3 first posted: Sanofi, Frexalimab + Frexalimab (NCT07412470)
- 2025-10-20Phase 3 first posted: Boston Children's Hospital, Everolimus blinded oral capsules + Placebo (NCT07218575)
- 2025-10-02Phase 3 first posted: Vertex Pharmaceuticals Incorporated, Povetacicept + Tacrolimus (NCT07204275)
- 2025-08-08Results posted on the registry: University of Pennsylvania, Sirolimus (NCT03933904)
- 2025-07-14Phase 3 first posted: Pfizer, PF-07248144 + Fulvestrant (NCT07062965)
- 2025-06-17Phase 3 first posted: Shandong Suncadia Medicine Co., Ltd., HRS-8080 Tablet + Fulvestrant injection (NCT07024173)
- 2025-05-30Results posted on the registry: University of Pennsylvania, Itacitinib + Everolimus (NCT03697408)
- 2025-05-08Phase 3 first posted: Biogen, Felzartamab + Tacrolimus (NCT06962800)
- 2025-04-30Phase 3 first posted: Rapamycin Holdings Inc., eRapa (encapsulated rapamycin) + Placebo (NCT06950385)
- 2025-04-29Results posted on the registry: Merck Sharp & Dohme LLC, Belzutifan + Everolimus (NCT04195750)
- 2025-04-24Phase 3 first posted: Exelixis, Zanzalintinib + Everolimus (NCT06943755)
- 2025-03-05Results posted on the registry: Abramson Cancer Center at Penn Medicine, Hydroxychloroquine + Everolimus (NCT03032406)
- 2025-02-12Phase 3 first posted: Incyte Corporation, INCA034176 + Best Available Therapy (BAT) (NCT06821542)
- 2025-02-11Results posted on the registry: National Cancer Institute (NCI), Sapanisertib (NCT03047213)
- 2024-11-29Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Alemtuzumab + Sirolimus (NCT02105766)
- 2024-11-08Phase 3 first posted: Jiangsu Simcere Pharmaceutical Co., Ltd., SIM0270 + Everolimus (Afinitor®) (NCT06680921)
- 2024-10-09Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), lulizumab pegol + antithymocyte globulin (rabbit) (NCT04066114)
- 2024-10-09Results posted on the registry: Weill Medical College of Cornell University, Fludarabine + Melphalan (NCT01810588)
- 2024-10-08Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Polyclonal Regulatory T Cells + Everolimus (NCT02711826)
- 2024-10-01Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Dactinomycin (NCT02567435)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision